… MS field, since IFN-β is about to come off patent and the present analysis may help to
convince the regulatory agencies to accept surrogate outcomes for assessing IFN-β biosimilars. …

… literature’s systematic reviews and on the indication of recommendation’s level [5] in order
to support the scientific evidence and to derive the best current scientific one. In the decision…

… atypical condition, the biological characteristics of which have not been defined yet. We
investigated the in situ immunophenotypical and transcriptional characteristics of a non‐clonal …

… latecomer’s resource-based theory and institutional theory. Using DEMATEL method, our …
entrepreneurial activities and constraints, the unit of analysis in this study is designed as the …

This study is dedicated to the political economy of the medical biotechnology industry in the
United States. The study combines interviews with more than 150 biotechnology actors with …

… aggregates, and lipid cloaked virions, are described in greater detail in another review [14].
Given the context of this review, we have used the term viral aggregate to refer to multi-unit …

… Fortunately, he said, the trial design included a prespecified interim analysis. This analysis
showed that nusinersen improved both survival and motor function; these observations …

… Biosimilars Approved versions of innovator biopharmaceutical products. Bioterrorism A …
narrow clinical topic which resembles a systematic review but is shorter and less comprehensive. …